Centiva Capital, LP Exelixis, Inc. Transaction History
Centiva Capital, LP
- $4.79 Billion
- Q3 2024
A detailed history of Centiva Capital, LP transactions in Exelixis, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 14,641 shares of EXEL stock, worth $513,167. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,641
Previous 15,632
6.34%
Holding current value
$513,167
Previous $351,000
7.98%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding EXEL
# of Institutions
495Shares Held
244MCall Options Held
2.4MPut Options Held
2.21M-
Black Rock Inc. New York, NY33.5MShares$1.17 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.03 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$891 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$538 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$401 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.3B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...